21:19 , Nov 18, 2016 |  BC Week In Review  |  Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
23:50 , Nov 15, 2016 |  BC Extra  |  Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

AMT-110: Phase I/II data

Top-line data from an open-label, French Phase I/II trial in 4 patients ages 20-53 months with Sanfilippo type B syndrome showed that a single administration of intracerebral AMT-110 plus continuous immune suppression therapy with mycophenolate...
07:00 , Sep 28, 2015 |  BioCentury  |  Product Development

Sailing on in Sanfilippo

uniQure N.V. says Phase I/II data on AMT-110 support both the start of a pivotal trial for Sanfilippo type B syndrome, and the company's plans to use its AAV5 vector in other rare lysosomal storage...
03:58 , Sep 22, 2015 |  BC Extra  |  Clinical News

uniQure to pursue pivotal trial of Sanfilippo B therapy

uniQure N.V. (NASDAQ:QURE) plans to advance AMT-110 into a pivotal trial after partner Institut Pasteur presented data from a four-patient Phase I/II trial of the gene therapy to treat Sanfilippo B. Results were presented at...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis N-acetylglucosaminidase-a (NAGLU); insulin-like growth factor-2 (IGF-2); mannose-6-phosphate receptor (M6P receptor) Mouse studies suggest a NAGLU-IGF-2 fusion protein could help treat mucopolysaccharidosis IIIB and...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Clinical News

Amsterdam Molecular preclinical data

In mice, a single IV dose of AMT-110 reduced serum cholesterol by about 80% with no signs of toxicity. Additionally, AMT-110 led to prolonged gene silencing of apolipoprotein B-100 (APOB-100) with no liver toxicity or...